It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Startseite > Publikationen

Phase-III-Studien

Daten aus den HAWK- und HARRIER-Studien, Woche 96

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, et al. HAWK and HARRIER: 96-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-related Macular Degeneration. Ophthalmologie 2020; im Druck.

Daten aus den HAWK- und HARRIER-Studien, Woche 48

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmologie 2020; 127: 72–84.

Phase-II-Studien

OSPREY-Studie

Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 2017; 124: 1296–304.

SEE-Studie

Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology 2016; 123: 1080–9.

Berichte des Komitees zur Bewertung von Sicherheitsdaten

Vorläufiger Bericht

Komitee zur Bewertung von Sicherheitsdaten (SRC). Novartis-Appointed Safety Review Committee Reports Initial Brolucizumab Findings. Veröffentlicht Juni 2020